EC Number   |
Activating Compound |
Reference |
|---|
   3.4.21.B6 | CHAPS |
increases enzyme activity up to 4fold with increasing concentration |
671687 |
| 3.4.21.B6 | DMSO |
increases enzyme activity up to 2fold with increasing concentration |
671687 |
| 3.4.21.B6 | hepsin |
hepsin activates prostasin by cleaving in the amino-terminal pro-peptide region of prostasin at Arg44 |
709925 |
| 3.4.21.B6 | Ibuprofen |
application of ibuprofen increases prostasin expression in the UROtsa and the B6Tert-1 cells. The ibuprofen-induced prostasin contributes to the formation and maintenance of the epithelial tight junctions in the B6Tert-1 cells. The matriptase zymogen wis down-regulated in the UROtsa cells by ibuprofen |
753089 |
| 3.4.21.B6 | matriptase |
- |
681036 |
| 3.4.21.B6 | matriptase |
matriptase activates prostasin by cleaving in the amino-terminal pro-peptide region of prostasin at Arg44 |
709925 |
| 3.4.21.B6 | matriptase |
prostasin activation is dependent on matriptase, prostasin activation is temporally coupled to matriptase autoactivation, prostatin activation is suppressed by matriptase knockdown and by blocking matriptase activation with sodium chloride |
709134 |
| 3.4.21.B6 | matriptase |
prostasin is proteolytically activated by matriptase |
707869 |
| 3.4.21.B6 | matriptase |
soluble matriptase efficiently converts soluble prostasin zymogen to an active two-chain form by endoproteolytic cleavage after Arg12 within the amino acid sequence QPR12-ITG |
680706 |
| 3.4.21.B6 | more |
increases in urine of patients affected by primary aldosteronism after volume expansion |
673953 |
